March 28th, 2024

VaxForm at World Vaccine Congress   Washington, DC, April 1st– April 4th, 2024.

Stop by our poster to learn about the latest results on our Phase I clinical trial evaluating safety and immunogenicity of oral COVID-19 vaccine

           Poster Zone: April 2 at 2:00 pm, April 3rd at 1:10 pm, April 4th at 12:30 pm

Looking for partnerships to advance our technologies:

          QYNDR platform: mucosal delivery of thermostable vaccines

          Group A Strep vaccine

Learn how we can help enhance your vaccine formulation: thermostabilization of mRNA LNP, subunit vaccines, alternative routes of administration, adjuvantation, etc. 

VaxForm publishes manuscript in Vaccines entitled " Group A Streptococcus Vaccine Targeting the Erythrogenic Toxins SpeA and SpeB Is Safe and Immunogenic in Rabbits and Does Not Induce Antibodies Associated with Autoimmunity"

https://www.mdpi.com/2076-393X/11/9/1504

Dr. Burlet was invited to give a talk at the 7th International Vaccines R&D conference, taking place in Boston, MA November 7th-9th. She will present VaxForm's latest work and findings on the pre-clinical development of our oral COVID-19 vaccine. 

https://vaccines.unitedscientificgroup.org/

Dr. Burlet was invited to give a talk on VaxForm's oral COVID-19 vaccine at the international conference Vaccine Technology VIII, taking place in Sitges, Spain, June 10th-16th. 

Vaccine Technology is the leading conference focused on the discovery, development and manufacture of vaccines. It brings together internationally leading experts to discuss the technologies and discoveries that have advanced vaccines for global needs.  

Dr. Burlet's presentation will be part of the "Formulation and Delivery" session. 

http://engconf.us/conferences/biotechnology/vaccine-technology-viii/#top

VaxForm and sister company USSF were featured in an episode of Living in the Lehigh Valley on PBS39. Watch the episode from April 18th on oral COVID-19 vaccines to learn more about VaxForm's oral delivery platform technology and its progress through clinical development thanks to their partnership with USSF. 

https://www.wlvt.org/television/living-in-the-lehigh-valley/ 

Dr. Brett Gershman, post-doctoral research associate at VaxForm, will present some of our work on COVID-19 vaccine development at the NFID Virtual 2021 Annual Conference on Vaccinology Research (ACVR) taking place April 26-27, 2021. His Abstract titled “Development of a recombinant protein subunit vaccine against COVID-19 with a novel adjuvant system to induce a balanced Th1/Th2 immune response" was selected for an oral presentation. 

Dr. Garry Morefield, President of VaxForm, was featured on WDIY, Lehigh Valley public radio. Listen to the recording to learn more about VaxForm and hear an update on our efforts to develop an oral COVID-19 vaccine. 

 OraSure's Dr. Stephen Tang & VaxForm's Dr. Garry Morefield | Teen Scientist | WDIY 

VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to support the development of their oral COVID-19 vaccine candidate.

 Awardees phase 1 details | NSF SBIR 

VaxForm is awarded $300,000 from the PA Department of Community and Economic Development to support the development of their oral COVID-19 vaccine candidate.

Wolf Administration Awards $10 Million to 23 Entities to Develop Effective COVID-19 Vaccines, Treatments and Therapies - PA Department of Community & Economic Development 

VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to further develop their oral vaccine delivery platform. The project is entitled: "Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphtheria Tetanus Pertussis vaccine."

 SBIR Phase I: Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphteria-Tetanus-Pertussis vaccine | SBIR.gov 

VaxForm publishes their latest results from the pre-clinical development of their recombinant fusion protein vaccine targeting Streptococcus Pyogenes bacteria in AAPS Journal. The vaccine successfully induced neutralizing antibodies in mice and displayed robust stability.

 Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes - PubMed (nih.gov)  

VaxForm publishes the results of the non-clinical safety studies of their vaccine candidate for Streptococcus Pyogenes. Rabbits were administered the maximum anticipated dose of the vaccine and exhibited no significant adverse reaction events. This is a great milestone achievement towards the initiation of first-in-human clinical trial of the vaccine. 

 Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant - PubMed (nih.gov)